Avectas becomes resident of Canadian bio hub

By The Science Advisory Board staff writers

November 5, 2020 -- Avectas has become a resident at Johnson & Johnson Innovation (JLABS), a 40,000-sq-ft life science innovation center in Toronto, Canada.

The labs provide a flexible space for companies pursuing new technologies and research platforms. Johnson & Johnson Innovation does not take equity stakes in the companies occupying JLABS and the companies are free to develop products and establish external partnerships and collaboration as they see fit.

Avectas is the developer of Solupore, a patented, nonviral cell engineering technology for transfection in cell and gene therapy applications. The company partners with cell and gene therapy companies to address engineering cell delivery challenges, specifically cell modifications and engineering fragile or limited cells.

Avectas has also appointed Jessica Schwaber, PhD, as scientific director of cell and gene therapy as the first member of the technical operations team at the Toronto site.

Avectas, UCD partner on cell engineering
Avectas and the Simon Laboratory at UC Davis, California (UCD) will work together on cell-engineering technology.
Avectas, ONK to develop cancer cell therapy
Avectas has exclusively licensed a chimeric antigen receptor-directed natural killer cell therapy from ONK Therapeutics for the treatment of B-cell malignancies...
Avectas nets patent for cell engineering technology
Avectas has received a patent for its Solupore cell engineering technology.
Vycellix, Avectas partner for product development
Vycellix and Avectas have unveiled plans to collaborate on the development of cell-based immunotherapeutic products.

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter